Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 4 Ovarian Neoplasms 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Neoplasms 1 Melanoma 1 Liver Diseases 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 aldesleukin 134 Cyclophosphamide 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 67 dabrafenib 65 fludarabine phosphate 61 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 cobimetinib 32 Magnetic Resonance Spectroscopy 32 Introns 30 Specimen Handling 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × rubitecan × Clear all

NCT00005875 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡